CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Chicago, Illinois, United States and 83 other locations
to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung...
Phase 2
Hinsdale, Illinois, United States and 96 other locations
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Phase 1
Chicago, Illinois, United States and 30 other locations
combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:* E...
Phase 2
Arlington Heights, Illinois, United States and 25 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Chicago, Illinois, United States and 210 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Chicago, Illinois, United States and 122 other locations
This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as...
Phase 3
Tinley Park, Illinois, United States and 30 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Chicago, Illinois, United States and 50 other locations
in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...
Phase 1, Phase 2
Chicago, Illinois, United States and 58 other locations
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently ...
Phase 1
Chicago, Illinois, United States and 20 other locations
Clinical trials
Research sites
Resources
Legal